This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GLAD | |
|---|---|
| Name | GLAD |
GLAD
GLAD is an eponymous designation used in some clinical and research contexts to denote a specific disorder characterized by distinct clinical, pathological, and epidemiological features. It is recognized within specialist centers, academic hospitals, and research consortia and is the subject of ongoing investigation by investigators affiliated with universities, institutes, and professional societies.
GLAD is described in literature produced by clinicians from institutions such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, University of Oxford, Karolinska Institutet, Imperial College London, University of Tokyo, Harvard Medical School, Stanford University School of Medicine, and University of California, San Francisco. Case series have been reported in journals associated with New England Journal of Medicine, The Lancet, JAMA, BMJ, Nature Medicine, and Science Translational Medicine. Multicenter collaborations have included investigators from World Health Organization, European Medicines Agency, National Institutes of Health, Centers for Disease Control and Prevention, Wellcome Trust, Bill & Melinda Gates Foundation, and various national health services. Consensus statements and classification proposals have been discussed at meetings of American College of Physicians, Royal College of Physicians, European Society of Cardiology, American Thoracic Society, and specialty workshops at American Academy of Neurology conferences.
Descriptions leading to the formal recognition of GLAD emerged from case reports by clinicians at Guy's Hospital and comparative pathology studies at Institut Pasteur and Max Planck Institute laboratories. Early epidemiologic clusters were described in cohort studies originating from Framingham Heart Study investigators and retrospective reviews at Mount Sinai Health System and Cleveland Clinic. Diagnostic criteria evolved through expert panels convened by National Institute for Health and Care Excellence and task forces sponsored by International Society for Infectious Diseases and specialty associations. Regulatory review and nomenclature debates involved stakeholders from Food and Drug Administration and academic editorial boards of Annals of Internal Medicine.
Patients present to centers such as Royal Free Hospital, Toronto General Hospital, Karolinska University Hospital, and Hospital Clínic de Barcelona with a spectrum of signs that overlap with syndromes described by clinicians at Mayo Clinic and Johns Hopkins Hospital. Diagnostic workups often involve imaging modalities developed at Massachusetts General Hospital radiology departments and laboratory assays standardized by laboratories at Washington University in St. Louis and University College London. Differential diagnoses considered include entities previously characterized at Beth Israel Deaconess Medical Center, St. Thomas' Hospital, Sheba Medical Center, and Ruijin Hospital. Diagnostic pathways reference classification frameworks from World Health Organization and testing algorithms endorsed by American College of Radiology and European Respiratory Society when applicable.
Investigations into etiology have involved geneticists from Broad Institute, Wellcome Sanger Institute, and European Molecular Biology Laboratory, and have drawn on mechanistic studies from laboratories at Salk Institute, Cold Spring Harbor Laboratory, and Max Delbrück Center for Molecular Medicine. Pathophysiologic models refer to pathways explored by researchers affiliated with National Institutes of Health intramural programs and university centers such as University of Cambridge and Johns Hopkins University. Proposed mechanisms have been compared with molecular signatures reported in cohorts assembled at UK Biobank, Framingham Heart Study, and EPIC Study datasets, and immunologic correlates evaluated by groups at Pasteur Institute and Institut National de la Santé et de la Recherche Médicale.
Management strategies have been developed in multidisciplinary teams at UCLA Health, Mount Sinai Hospital, Cedars-Sinai Medical Center, Royal Melbourne Hospital, and regional referral centers. Therapeutic options mirror approaches trialed in randomized studies coordinated by networks such as ClinicalTrials.gov-registered consortia and cooperative groups including European Organisation for Research and Treatment of Cancer and National Cancer Institute cooperative trials, adapted as appropriate. Interventions draw on pharmacologic agents developed by companies collaborating with translational units at Genentech, Roche, Pfizer, and academic spin-outs from MIT and University of Pennsylvania. Supportive care pathways reference guidelines from American Heart Association, American College of Chest Physicians, European Society of Cardiology, and American Thoracic Society.
Epidemiologic patterns have been characterized using registries maintained by National Institutes of Health, national health agencies such as Public Health England, Robert Koch Institute, and surveillance networks coordinated with European Centre for Disease Prevention and Control. Incidence and prevalence estimates rely on datasets from population cohorts including UK Biobank, NHS Digital, SEER Program, and longitudinal studies such as Framingham Heart Study and Nurses' Health Study. Geographic clustering and demographic associations have been reported in region-specific analyses from Istituto Superiore di Sanità and national registries in Japan, Canada, Australia, and several European countries.
Ongoing research is being conducted at translational centers including Broad Institute, Dana-Farber Cancer Institute, Scripps Research Institute, Weizmann Institute of Science, RIKEN, and academic departments at University of Oxford and Harvard Medical School. Future priorities endorsed by panels convened at meetings of World Health Organization and specialty societies include biomarker discovery using platforms developed at Illumina, precision medicine trials modeled on initiatives at National Institutes of Health and consortium efforts supported by Gates Foundation and Wellcome Trust. Collaborative networks and data-sharing initiatives involve partners from European Molecular Biology Laboratory, Global Alliance for Genomics and Health, and major academic medical centers to accelerate validation of diagnostics, therapeutic trials, and health services research.
Category:Medical conditions